RegeneRx reports positive results from phase II venous stasis ulcers trial

According to Regenerx, RGN-137 is a topical gel formulation of thymosin beta 4 peptide. The drug candidate was found to be safe and well-tolerated at all three dose levels, with no dose-limiting or drug-related adverse events, which was the primary objective of the trial. Like the previously reported phase II pressure ulcer trial, the mid-dose level of RGN-137 appeared to be the most active of the three doses and induce more rapid initiation of wound healing compared to placebo.

Approximately two key parameters were evaluated in the primary efficacy population (all 72 randomized patients receiving at least one dose of drug or placebo): percent of patients with complete wound healing and time to complete wound healing.

Approximately 33% of the patients in the mid-dose group had complete healing compared to 24% in the placebo group, 16% in the low-dose group, and 17% in the high-dose group. Of those patients in the mid-dose group with complete healing, it was observed that RGN-137 decreased the median time to complete healing by approximately 40% compared to placebo. The differences between the active dose groups and placebo were not deemed to be statistically significant.

The trial was sponsored by RegeneRx and conducted in Italy and Poland by its partner and largest stockholder, Sigma-Tau Group. Approximately eight clinical sites in Italy and Poland enrolled and treated 72 patients in the double-blind, placebo-controlled, phase II clinical trial to evaluate the safety, tolerability, and wound healing effects of three escalating concentrations of thymosin beta 4 peptide (0.01%, 0.03%, and 0.1%) compared to placebo. All patients were randomized to receive standard of care, plus drug or placebo applied topically, once daily for up to 84 consecutive days. The average age of the patients was 60 years.

David Crockford, vice president of clinical and regulatory affairs at RegeneRx, said: “We are pleased the trial met the primary objective of safety, and that we were able to see evidence of wound healing activity in patients with venous ulcers, which are very difficult to treat. We believe that the observations in the mid-dose group, along with data obtained from our recently completed phase II pressure ulcer trial, provide important information suggesting that the mid-dose of RGN-137 initiated the wound healing process earlier than the low-dose, high-dose or placebo.”